Sr Buchman

Abstract 62: A NOVEL COMBINATION OF AMIFOSTINE PROPHYLAXIS AND ANGIOGENIC DEFEROXAMINE PROTECTS AND RESTORES BIOMECHANICAL PROPERTIES OF BONE IN PATHOLOGIC FRACTURE HEALING AFTER RADIOTHERAPY

Purpose: Pathologic fractures and associated non-unions after radiotherapy for Head and Neck cancer pose a complex management dilemma for reconstructive surgeons. We have previously demonstrated a partial remediation of biomechanical strength and bony union formation with Deferoxamine (DFO), an angiogenic factor, in a murine model of fracture healing following radiotherapy. The purpose of this study was to investigate the synergistic potential of Amifostine (AMF), a cytoprotectant, in combination with DFO to produce a more robust biomechanical construct and predictable rate of bony union.

Abstract 211: DEFEROXAMINE RESTORES BIOMECHANICAL PROPERTIES AND POTENTIATES UNION OF IRRADIATED BONE IN DISTRACTION OSTEOGENESIS

Background: Our laboratory has shown the iron-chelating agent Deferoxamine (DFO) promotes angiogenesis and bone repair in the setting of radiation therapy (XRT) coupled with Distraction Osteogenesis (DO). While these studies demonstrate DFO improves vascular and histologic metrics for irradiated bone, the clinically impactful effect of DFO on union formation and biomechanics has never been examined. We hypothesize DFO administration will increase bony union and strengthen Biomechanical Properties (BPs) of the regenerate in an irradiated DO model.